Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma

Background/objectives: Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are susceptible to viral infections, including varicella-zoster virus (VZV) reactivation due to both disease-related and treatment-induced immunosuppression. The recombinant adjuvanted herpes zoster vaccine (RZV) has shown high efficacy in immunocompetent adults, but immunogenicity data in CLL and MM patients are limited. This study evaluates the immunogenicity and safety of RZV in this population.

Methods: Patients with CLL and MM vaccinated with RZV (administered in two doses at least one month apart) were included in the study. Pre- and post-vaccination anti-VZV IgM and IgG antibody levels were measured to assess immunogenicity, and adverse events (AEs) were captured for safety evaluation.

Results: Seventy-eight patients received both vaccine doses, and 71 had post-vaccination samples. Most of the patients were IgM seronegative and IgG seropositive before vaccination. Pre-vaccination IgG levels were higher in CLL patients compared to MM patients ( = 0.001), while post-vaccination IgG levels significantly increased in both CLL ( < 0.0001) and MM ( < 0.0001) patients. In actively treated CLL patients, pre-vaccination IgG levels were significantly lower than in not actively treated patients ( = 0.002). Post-vaccination IgG levels were lower in MM patients receiving antiviral prophylaxis concurrently with the vaccination ( = 0.013). AEs were reported in 49.4% of patients after the first dose and 48.7% after the second dose, mostly mild (local or low-grade systemic). One case of immune thrombocytopenia was noted.

Conclusions: RZV demonstrated strong immunogenicity and acceptable safety in CLL and MM patients, significantly boosting IgG levels, even in actively treated or heavily pretreated patients.

References

Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher J . Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018; 17(7):619-634. DOI: 10.1080/14760584.2018.1495565. View

Dooling K, Guo A, Patel M, Lee G, Moore K, Belongia E . Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018; 67(3):103-108. PMC: 5812314. DOI: 10.15585/mmwr.mm6703a5. View

Oostvogels L, Heineman T, Johnson R, Levin M, McElhaney J, van den Steen P . Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019; 15(12):2865-2872. PMC: 6930113. DOI: 10.1080/21645515.2019.1627818. View

Lal H, Cunningham A, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 372(22):2087-96. DOI: 10.1056/NEJMoa1501184. View

Pleyer C, Ali M, Cohen J, Tian X, Soto S, Ahn I . Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2020; 137(2):185-189. PMC: 7820878. DOI: 10.1182/blood.2020008758. View

Callegaro A, Burny W, Herve C, Kim J, Levin M, Zahaf T . Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. J Infect Dis. 2021; 226(11):1943-1948. PMC: 9704432. DOI: 10.1093/infdis/jiab536. View

Losa L, Antonazzo I, Di Martino G, Mazzaglia G, Tafuri S, Mantovani L . Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression. Vaccines (Basel). 2024; 12(5). PMC: 11125663. DOI: 10.3390/vaccines12050527. View

Gidengil C, Goetz M, Newberry S, Maglione M, Hall O, Larkin J . Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine. 2021; 39(28):3696-3716. DOI: 10.1016/j.vaccine.2021.03.079. View

Boutry C, Hastie A, Diez-Domingo J, Tinoco J, Yu C, Andrews C . The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis. 2021; 74(8):1459-1467. PMC: 9049256. DOI: 10.1093/cid/ciab629. View

10.

Ocran-Appiah J, Boutry C, Herve C, Soni J, Schuind A . Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. Vaccine. 2020; 39(1):6-10. DOI: 10.1016/j.vaccine.2020.10.029. View

11.

Maple P, Rathod P, Smit E, Gray J, Brown D, Boxall E . Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. J Clin Virol. 2008; 44(1):9-14. DOI: 10.1016/j.jcv.2008.08.012. View

12.

Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze F . Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019; 37(18):2482-2493. DOI: 10.1016/j.vaccine.2019.03.043. View

13.

Schmader K, Levin M, Gnann Jr J, McNeil S, Vesikari T, Betts R . Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54(7):922-8. PMC: 4542655. DOI: 10.1093/cid/cir970. View

14.

Esteban-Vazquez A, Steiner M, Castaneda E, Andreu-Vazquez C, Thiussard I, Somodevilla A . The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors. Vaccines (Basel). 2023; 11(10). PMC: 10610564. DOI: 10.3390/vaccines11101610. View

15.

Gan G, Liu H, Liang Z, Zhang G, Liu X, Ma L . Vaccine-associated thrombocytopenia. Thromb Res. 2022; 220:12-20. DOI: 10.1016/j.thromres.2022.09.017. View

16.

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

17.

Xia Y, Zhang X, Zhang L, Fu C . Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front Immunol. 2022; 13:978203. PMC: 9561817. DOI: 10.3389/fimmu.2022.978203. View

18.

Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Abeele C . Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine. 2017; 36(1):148-154. DOI: 10.1016/j.vaccine.2017.11.019. View

19.

Chanan-Khan A, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau J . Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26(29):4784-90. DOI: 10.1200/JCO.2007.14.9641. View

20.

Mikulska M, Cesaro S, de Lavallade H, Di Blasi R, Einarsdottir S, Gallo G . Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(6):e188-e199. DOI: 10.1016/S1473-3099(18)30601-7. View